HSBC analyst Yifeng Liu upgraded Moderna (MRNA) to Buy from Hold with a price target of $58, down from $82. The recent share ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Live Updates Stocks on the Move Today 9:49 am Here are some notable stocks on the move today: Super Micro Computer: The ...

Stocks rebounded after last week’s slide as Treasuries stabilized after 10-year yields approached 4.5%, with traders keeping ...

That includes Big Tech, which is currently making a series of peculiar investments in a few strange companies. This has nothing to do with tech. At least on the surface … Yet, these strange ...

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.

CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Nvidia's revenue is forecast to jump more than 80% to $33 billion, according to estimates compiled by LSEG, and the company ...

On Thursday, Moderna Inc (MRNA) stock saw a decline, ending the day at $39.77 which represents a decrease of $-2.37 or -5.62% from the prior close of $42.14. The stock opened at $42.05 and touched a ...